SMO and neoplasm: However, at what level of the signaling pathway a cancer cell has acquired such a pathway-activating genetic aberration will evidently determine whether, or not, a specific inhibitor is efficacious, as tumours with activating mutations downstream of SMO will be insensitive to the majority of Hh pathway inhibitors under development today.